Jeffrey Sweeney, MD
Family Medicine · Shenandoah, TXNPI 1750479465
Payments from drug & device makers
Across 91 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$444
- Abbott$164
- Amgen$156
- Inspire Medical Systems, Inc.$130
- Astellas Pharma US Inc$114
- GSK$89
- plus $696 from 22 others
What the payments were for
- Food & beverage$1,794100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 21 | $444 |
| Abbott | 8 | $164 |
| Amgen | 8 | $156 |
| Inspire Medical Systems, Inc. | 7 | $130 |
| Astellas Pharma US Inc | 6 | $114 |
| GSK | 4 | $89 |
| Novo Nordisk | 5 | $86 |
| Boston Scientific | 4 | $80 |
| AbbVie(2 entities) | 4 | $68 |
| Stryker | 1 | $59 |
| Vertiflex, Inc. | 3 | $58 |
| Pfizer | 2 | $35 |
| Lilly USA, LLC | 2 | $34 |
| Irhythm Technologies, Inc. | 1 | $32 |
| Shire North American Group Inc | 2 | $28 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$1,794 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $160,805 |
| JanuviaSitagliptin Phosphate | 131 | $138,061 |
| JardianceEmpagliflozin | 99 | $136,445 |
| MounjaroTirzepatide | 72 | $109,371 |
| EliquisApixaban | 76 | $78,968 |
| TrulicityDulaglutide | 53 | $68,755 |
| XareltoRivaroxaban | 45 | $56,147 |
| FarxigaDapagliflozin Propanediol | 25 | $37,251 |
| LinzessLinaclotide | 22 | $20,476 |
| WegovySemaglutide | 12 | $15,175 |
| VascepaIcosapent Ethyl | 21 | $13,140 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $10,250 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,784 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $7,022 |
| Atorvastatin Calcium | 714 | $6,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $34 | $178,126125 claims |
| Novo NordiskOzempic, Wegovy | $86 | $175,980143 claims |
| Boehringer IngelheimJardiance | $17 | $136,44599 claims |
| PfizerEliquis | $35 | $78,96876 claims |
| Johnson & JohnsonXarelto | $19 | $56,14745 claims |
| AstraZenecaFarxiga, Symbicort | $14 | $42,63738 claims |
| AbbVieLinzess, Synthroid | $68 | $25,429119 claims |
| GSKBreo Ellipta | $89 | $7,78416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Shenandoah
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.